Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unichem LaboratoriesNSE:UNICHEMLAB +1.19%73 EV-to-EBITDA is 8.92 as of Jul. 26, 2026, which is 42% below its 10-year median of 15.41. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 73/100 and a GF Value™ of ₹681.70 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 742 Drug Manufacturers companies, Unichem Laboratories ranks better than 66.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Unichem Laboratories's enterprise value is ₹40,073 Mil.
Unichem Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4,491 Mil. Therefore, Unichem Laboratories's EV-to-EBITDA for today is 8.92.
The historical rank and industry rank for Unichem Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:UNICHEMLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -248.05 Med: 15.41 Max: 289.14
Current: 8.92
During the past 13 years, the highest EV-to-EBITDA of Unichem Laboratories was 289.14. The lowest was -248.05. And the median was 15.41.
NSE:UNICHEMLAB's EV-to-EBITDA is ranked better than 66.98% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs NSE:UNICHEMLAB: 8.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Unichem Laboratories's PE Ratio (TTM) for today is calculated as:
Unichem Laboratories's share price for today is ₹537.35.
Unichem Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Unichem Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:UNICHEMLAB vs ZTS, UTHR: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unichem Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Unichem Laboratories's EV-to-EBITDA falls into.
Unichem Laboratories's current Enterprise Value is ₹40,073 Mil.
Unichem Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,491 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unichem Laboratories (NSE:UNICHEMLAB) has a EV-to-EBITDA of 8.92 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Unichem Laboratories. This is 42% below median its historical median of 15.41. According to the industry distribution chart, Unichem Laboratories ranks #245 out of 742 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Unichem Laboratories' EV-to-EBITDA too high?
Unichem Laboratories' current EV-to-EBITDA of 8.92 is 42% below median its 10-year median of 15.41. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Unichem Laboratories' value of 8.92 is 31.3% below this industry median. Based on the distribution chart, Unichem Laboratories ranks #245 out of 742 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Unichem Laboratories has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unichem Laboratories ranks #245 out of 742 companies for EV-to-EBITDA. This puts Unichem Laboratories in the upper half of its industry. The industry median EV-to-EBITDA is 12.98. Unichem Laboratories' value of 8.92 is 31.3% below this benchmark. While the company's 10-year median is 15.41 vs. the industry median of 12.98, Unichem Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unichem Laboratories's current EV-to-EBITDA of 8.92 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Unichem Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unichem Laboratories's current EV-to-EBITDA is 8.92, which is 42% below median its own 10-year median of 15.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹681.70, compared to a current price of ₹537.35 — trading 21.2% below its estimated fair value. The current EV-to-EBITDA is 8.92, which is 42% below median its 10-year median of 15.41 and 31.3% below the Drug Manufacturers industry median of 12.98. Unichem Laboratories' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current EV-to-EBITDA is 8.92 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued.
The current stock price of ₹537.35 is trading 21.2% below its estimated GF Value™ of ₹681.70.
GuruFocus considers Unichem Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:UNICHEMLAB:
EV-to-EBITDA: 8.92 (42% below median its 10-year median of 15.41)
GF Value™: ₹681.70 vs. price of ₹537.35 (21.2% below fair value)
Industry Position: 31.3% below the Drug Manufacturers median (#245 of 742)
No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
73GF Score
Get the complete analysis for NSE:UNICHEMLAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:UNICHEMLAB has been successfully added to your 
